Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPD | P32754 | 9/20 | 0.64 |
| ▸ | MAOB | P27338 | 6/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 4/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8088242 | 0.81 | MAOB (0.63) | MAOBMAPTSMN1; SMN2MAOA | |
| SCHEMBL10908860 | 0.80 | POLB (0.47) | HPDMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2986814 | 0.79 | HPD (0.57) | HPD | |
| SCHEMBL31529361 | 0.78 | KMT2A (0.51) | HPDMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL6552022 | 0.78 | MAPT (0.54) | HPDMAOBMAPTSMN1; SMN2CYP19A1 | |
| SCHEMBL4944452 | 0.76 | KMT2A (0.62) | MAOBMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4869351 | 0.76 | TDP1 (0.50) | MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL30662860 | 0.76 | KMT2A (0.54) | HPDSMN1; SMN2CYP19A1 | |
| SCHEMBL26604443 | 0.76 | KMT2A (0.54) | HPDSMN1; SMN2CYP19A1 | |
| SCHEMBL9671326 | 0.75 | HPD (0.54) | HPDNPC1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269344-A1 | Beta2-Adrenergic Receptor Agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-10-30 | — | — | US | disclosed |
| US-7427639-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-20070179179-A1 | Beta2-adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-08-02 | — | — | US | disclosed |
| US-7217738-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-20050261338-A1 | Beta2-adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-11-24 | — | — | US | disclosed |
| US-6916961-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2005-07-12 | — | — | US | disclosed |
| EP-1235787-B1 | $g(b)2-ADRENERGIC RECEPTOR AGONISTS | THERAVANCE INC (US) | 2003-10-29 | — | — | EP | disclosed |
| US-6576793-B1 | β2-adrenergic receptor agonists | THERAVANCE, INC. | 2003-06-10 | — | — | US | disclosed |
| US-20030087307-A1 | Beta2-adrenergic receptor agonists | ADVANCED MEDICINE, INC. | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261338-A1 | Beta2-adrenergic receptor agonists | ADRB2, ADRB1, ADRA2B | HPD 4373/4885MAOB 442/4885MAPT 1964/4885 |
| US-20030087307-A1 | Beta2-adrenergic receptor agonists | ADRB2, ADRB1, ADRA2B | HPD 4302/4885MAOB 426/4885MAPT 1994/4885 |
| US-20080269344-A1 | Beta2-Adrenergic Receptor Agonists | ADRB2, ADRB1, ADRA2B | HPD 4373/4885MAOB 442/4885MAPT 1964/4885 |
| US-20070179179-A1 | Beta2-adrenergic receptor agonists | ADRB2, ADRB1, ADRA2B | HPD 4373/4885MAOB 442/4885MAPT 1964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.